Drug Information

Drug General Information
Drug ID
D08HOJ
Former ID
DNC012215
Drug Name
1,2,3,4-Tetrahydro-naphthalen-2-ylamine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [533482]
Formula
C10H13N
Canonical SMILES
C1CC2=CC=CC=C2CC1N
InChI
1S/C10H13N/c11-10-6-5-8-3-1-2-4-9(8)7-10/h1-4,10H,5-7,11H2
InChIKey
LCGFVWKNXLRFIF-UHFFFAOYSA-N
PubChem Compound ID
34677
Target and Pathway
Target(s) 5-hydroxytryptamine 2A receptor Target Info Inhibitor [533482]
5-hydroxytryptamine 1A receptor Target Info Inhibitor [533482]
5-hydroxytryptamine 1D receptor Target Info Inhibitor [533482]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channelshsa04024:cAMP signaling pathway
Serotonergic synapsehsa04024:cAMP signaling pathway
PANTHER Pathway 5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (i) signalling events
WikiPathways Serotonin Receptor 2 and STAT3 Signaling
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
SIDS Susceptibility Pathways
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
GPCRs, OtherWP722:Serotonin HTR1 Group and FOS Pathway
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
References
Ref 533482J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
Ref 533482J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.